UY38958A - Agonista del receptor glp-1 y uso de este - Google Patents

Agonista del receptor glp-1 y uso de este

Info

Publication number
UY38958A
UY38958A UY0001038958A UY38958A UY38958A UY 38958 A UY38958 A UY 38958A UY 0001038958 A UY0001038958 A UY 0001038958A UY 38958 A UY38958 A UY 38958A UY 38958 A UY38958 A UY 38958A
Authority
UY
Uruguay
Prior art keywords
glp
compounds
exhibit excellent
receptor agonist
receptor agonists
Prior art date
Application number
UY0001038958A
Other languages
English (en)
Inventor
Hong Chul Yoon
Kyung Mi An
Myong Jae Lee
Jin Hee Lee
Jeong-Geun Kim
Woo Jin Jeon
Jin Ah Jeong
Jaeho Heo
Changhee Hong
Kyeojin Kim
Jung-Eun Park
Te-Ik Sohn
Changmok Oh
Da Hae Hong
Sung Wook Kwon
Jung Ho Kim
Jae Eui Shin
Yeongran Yoo
Min Whan Chang
Eun Hye Jang
In-Gyu Je
Ji Hye Choi
Gunhee Kim
Yearin Jun
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of UY38958A publication Critical patent/UY38958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen compuestos novedosos de la Fórmula Química 1, isómeros ópticos de los compuestos, y sales farmacéuticamente aceptables de los compuestos o los isómeros ópticos. Los compuestos, isómeros, y sales exhiben excelente actividad como agonistas del receptor GLP-1. En particular, estos, como agonistas del receptor GLP-1, exhiben una excelente tolerancia a la glucosa, por ende, tienen un gran potencial de ser usados como agentes terapéuticos para enfermedades metabólicas. Asimismo, exhiben una excelente seguridad farmacológica para los sistemas cardiovasculares.
UY0001038958A 2019-11-15 2020-11-13 Agonista del receptor glp-1 y uso de este UY38958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190146798 2019-11-15
KR1020200022485A KR20210059584A (ko) 2019-11-15 2020-02-24 Glp-1 수용체 작용제 및 이의 용도

Publications (1)

Publication Number Publication Date
UY38958A true UY38958A (es) 2021-05-31

Family

ID=76145757

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038958A UY38958A (es) 2019-11-15 2020-11-13 Agonista del receptor glp-1 y uso de este

Country Status (4)

Country Link
KR (1) KR20210059584A (es)
AR (1) AR120458A1 (es)
TW (2) TW202128658A (es)
UY (1) UY38958A (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220152083A (ko) 2021-05-07 2022-11-15 주식회사 엘지화학 가교구조 함유 올레핀고분자 다공지지체, 이를 포함하는 리튬 이차전지용 가교구조 함유 분리막, 이의 제조 방법, 및 상기 분리막을 구비한 리튬 이차전지
CA3224598A1 (en) * 2021-08-30 2023-03-09 Long Zhang Novel aryl ether substituted heterocyclic compound as glp1r agonist
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
WO2023182869A1 (en) * 2022-03-25 2023-09-28 Ildong Pharmaceutical Co., Ltd. Novel salt of glp-1 receptor agonist compound, preparation method thereof and pharmaceutical composition comprising thereof
CN117362282A (zh) * 2022-07-07 2024-01-09 杭州德睿智药科技有限公司 Glp-1r激动剂的盐及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008012623A1 (en) * 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
JP6637641B1 (ja) * 2016-12-16 2020-01-29 ファイザー・インク Ｇｌｐ−１受容体アゴニストおよびその使用
KR20220092909A (ko) * 2019-10-25 2022-07-04 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물

Also Published As

Publication number Publication date
AR120458A1 (es) 2022-02-16
KR20210059584A (ko) 2021-05-25
TWI786467B (zh) 2022-12-11
TW202128658A (zh) 2021-08-01
TW202128659A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
CO2022006183A2 (es) Agonista del receptor glp-1 y uso de este
UY38958A (es) Agonista del receptor glp-1 y uso de este
DOP2020000201A (es) Compuestos heteroaril tetracíclicos
NI201900039A (es) Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2009000780A1 (es) Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k.
AR110299A1 (es) Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CL2016000495A1 (es) Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades.
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
UY36416A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa
CL2023003794A1 (es) Agonista del receptor de glp-1 y composición y uso del mismo
ECSP19062381A (es) Moduladores del receptor de estrógeno
AR061271A1 (es) Antagonistas de cgrp
AR107392A1 (es) Formulaciones / composiciones que comprenden un inhibidor de btk
CO2019010029A2 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
PE20211247A1 (es) Sulfonas y sulfoxidos biciclicos y metodos de usos de los mismos
UY38488A (es) Derivados de pirazol y su uso en medicina
AR107937A1 (es) Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer
CL2008001112A1 (es) Usos de compuestos derivados de pirido[2,3-d]pirimidin-4-ona para tratar comezon o un trastorno relacionado con comezon; combinacion de los compuestos con otro farmaco; y uso de la combinacion para tratar la comezon o un trastorno relacionado con comezon.